ERBB2 and breast cancer: Patients with LA-HR+/HER2- BC had a 35% increased risk of death (HR = 1.35; 95% CI 1.24–1.48; p < 0.0001) compared to those with ES-TNBC after adjusting for all covariates (Figure 1b).